212-Lead Pentixather

N/A

Report date: 2025/11/20 16:00:51
NME

Base Information

Drug Name212-Lead Pentixather
Drug Alias Name212-Pb Pentixather
ClassificationRadiation-emitting products > Nuclides > Lead > 212PbRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radionuclide Drug Conjugates +[4] 
Mechanisms of ActionC-X-C motif chemokine receptor 4 antagonists
TargetsC-X-C motif chemokine receptor 4
Therapy Area/IndicationsSmall Cell Lung CarcinomaLung Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesNational Institutes Of HealthNational Cancer InstituteHolden Comprehensive Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesHolden Comprehensive Cancer CenterNational Institutes Of HealthNational Cancer Institute
Inactive CompaniesN/A
Active IndicationsSmall Cell Lung CarcinomaLung Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A